Refractory IHCA and OHCA Treated With ECMO (SEAC)
Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
MB
-
Monza, MB, Italy, 20052
- Recruiting
- San Gerardo Hospital
-
Contact:
- Leonello Avalli, MD
- Phone Number: 0039392334330
- Email: l.avalli@hsgerardo.org
-
Contact:
- Roberto Fumagalli, MD
- Phone Number: 0039392339294
- Email: r.fumagalli@hsgerardo.org
-
Principal Investigator:
- Leonello Avalli, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults 18-75 years old
- In and out of hospital Witnessed Cardiac Arrest
- No-flow time < 5 min. or VF,VT,TP as rhythm of presentation
- Low-flow time < 45 min.
- End Tidal CO2 > 10 after 20 min.of CPR
Exclusion Criteria:
- Comorbidities such:
- Terminal Malignancy
- Aortic Dissection
- Severe Cardiac Failure without transplant indication
- Severe Aortic Valve Failure
- Known Severe Peripheral arteriopathy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Extracorporeal Membrane Oxygenation
All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
|
Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
28 days survival
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurologic recovery
Time Frame: 28 days
|
Neurologic recovery defined as minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.
|
28 days
|
|
Cardiac recovery
Time Frame: 28 days
|
Measured by echocardiography
|
28 days
|
|
Six months survival with minimal neurologic impairment
Time Frame: 180 days
|
survival with minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.
|
180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Leonelllo Avalli, MD, Ospedale San Gerardo
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AOSG-TICCH-01-2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.